| Gene symbol | CSF2 | Synonyms | CSF, GMCSF | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | colony stimulating factor 2 | ||||
| Gene symbol | E2F1 | Synonyms | E2F-1, RBAP1, RBBP3, RBP3 | Type of gene | protein-coding |
| Chromosome | 20 | Map location | 20q11.22 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | E2F transcription factor 1 | ||||
| GTO ID | GTC3968 |
| Trial ID | NCT04387461 |
| Disease | Bladder Cancer |
| Altered gene | E2F1|CSF2 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | CG0070|Cretostimogene Grenadenorepvec |
| Co-treatment | Pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Unknown |
| Title | A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) |
| Year | 2020 |
| Country | United States|Korea, Republic of |
| Company sponsor | CG Oncology, Inc. |
| Other ID(s) | CG2003C|Mk3475 Keynote 935 |
| Vector information | |||||||||||||||
|
|||||||||||||||
| Cohort 1 | |||||||||||
|
|||||||||||